Compare Cassava Sciences Inc (FLNA) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lockheed Martin Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Lockheed Martin Corporation trades at $509.59 (market cap $117.22B). The key difference: Lockheed Martin Corporation is far larger — about 2975.1× Cassava Sciences Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Lockheed Martin Corporation for 86 Days on average.
| FLNA | LMT | |
|---|---|---|
Market Cap | $39.40M | $117.22B |
Volume | 759,018 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $4.64 | $676.70 |
52-Week Low | $0.68 | $439.19 |
Typical Hold Time | 37 Days | 86 Days |
Enterprise Value | -$43.28M | $133.96B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q1 and Q4 2025 expectations, with revenue growth from $75.05B in 2025 to projected $77.0B in 2026. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains strongly bullish with a $635.33 price target.
LMT offers stable defense sector exposure with 23 consecutive dividend increases and strong cash flow, but faces execution risks on fixed-price contracts and competitive pressures. The stock trades at reasonable valuations (P/E 18.73, P/S 1.53) with high institutional support, though technical weakness near support at $503 requires monitoring for sustained upward momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
